At a glance
- Originator Sanofi-Synthelabo
- Class Antiretrovirals
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 21 Jul 1998 No development reported - Preclinical for HIV-1 infections in France (unspecified route)
- 21 Sep 1995 New profile
- 21 Sep 1995 Preclinical development for HIV-1 infections in France (Unknown route)